Stay updated on Pembrolizumab for Intermediate Risk NMIBC Clinical Trial
Sign up to get notified when there's something new on the Pembrolizumab for Intermediate Risk NMIBC Clinical Trial page.

Latest updates to the Pembrolizumab for Intermediate Risk NMIBC Clinical Trial page
- Check5 days agoNo Change Detected
- Check12 days agoChange DetectedAdded related topic tags 'Bladder cancer' and 'MedlinePlus Genetics' to the page, which are minor metadata enhancements and do not modify study details or user interactions. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.2%

- Check19 days agoChange DetectedA new Locations section lists Hampshire, Oxfordshire, and Surrey, and the page revision updated to v3.3.3. The standalone Hampshire/Oxfordshire/Surrey Locations subsections and the HHS Vulnerability Disclosure link were removed.SummaryDifference0.4%

- Check26 days agoNo Change Detected
- Check33 days agoChange DetectedRemoved related topics: 'Bladder cancer' and 'MedlinePlus Genetics' from the page's related topics section. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.2%

- Check41 days agoChange DetectedPage version updated from v3.2.0 to v3.3.2. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

- Check47 days agoChange DetectedThe top government funding status notice was removed; the study details, contacts, locations, and eligibility criteria remain unchanged. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.4%

- Check70 days agoChange DetectedNo significant changes detected in the study details page between versions. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.5%

Stay in the know with updates to Pembrolizumab for Intermediate Risk NMIBC Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Pembrolizumab for Intermediate Risk NMIBC Clinical Trial page.